• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

EFPIA, EBE, and Vaccines Europe Support EU on Combatting AMR


Pharmaceutical Executive

The European Federation of Pharmaceutical Industries and Associations (EFPIA), European Biopharmaceutical Enterprises (EBE), and Vaccines Europe have welcomed EU efforts to strengthen the fight against antimicrobial resistance (AMR) with the launch of the European Commission’s Action Plan on AMR, which proposes viable solutions that will benefit patients globally. In a joint statement, EFPIA, EBE, and Vaccines Europe announced they are standing behind the EU initiative and are calling on governments, multilateral institutions, the private sector, and civil society to follow through on the momentum provided by the UN, G7, G20, and the 67 national AMR action plans sponsored by governments across the world.


EFPIA, EBE, and Vaccines Europe emphasized industry’s commitment to measures focusing on reducing environmental impact resulting from the production of antibiotics, working with the AMR Alliance, the PSCI, and the Eco-Pharmaco-Stewardship (EPS) initiative to develop concrete solutions. They report that industry additionally is open to dialogue with all stakeholders responsible for the environment, and is working on the medsdisposal campaign to tackle the improper disposal of antibiotics.


In order to focus efforts on addressing unmet medical needs, EFPIA, EBE, and Vaccines Europe called upon the European Commission, in conversation with relevant sector stakeholders, to develop a European priority pathogens list-aligned with the existing WHO list-to help guide research priorities and fuel R&D in Europe.